Sign In
Last checked at 
15 Jun 2026 12:36
Β
Β
EKF Diagnostics Holdings plc
("EKF" or the "Company")
Β
Share Buyback
Β
EKF Diagnostics Holdings plcΒ (AIM: EKF), theβ―AIM-listed global diagnostics business, announces that it has purchased a total of 60,000 of its ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at a weighted average price of 25.0 pence per share. The purchased shares will be cancelled.
Β
Aggregated information
Β
Date of purchase | 12 June 2026 |
Number of Ordinary Shares purchased | 60,000 |
Highest price paid per Ordinary Share | 25.0p |
Lowest price paid per Ordinary Share | 25.0p |
Volume weighted average price paid | 25.0p |
Β
Β Transaction details
Β
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation)Β (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018), a detailed breakdown of individual trades is available below:
Β
Number of Ordinary Shares purchased | Transaction price (GBp) | Time of transaction | Trading venue |
60,000 | 25.0p | 14:05:31 | AIMX |
Β
Total voting rights
Β
Following the purchase and after the cancellation of the shares becomes effective, the Company's total issued share capital will consist ofΒ 430,273,112 Ordinary Shares. There are no shares held in treasury. Therefore, the total number of Ordinary Shares carrying voting rights will be 430,273,112. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Β
Β
Β
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).Β
Β
Β
The person responsible for arranging the release of this Announcementon behalf of the Company is Julian Baines, Executive Chair.
Β
Β
EKF Diagnostics Holdings plc | www.ekfdiagnostics.com | ||
Julian Baines, Executive Chair | Β via Walbrook PR | ||
Gavin Jones, Chief Executive Officer | |||
Β Singer Capital Markets (Nominated Adviser & Broker) | Tel: +44 (0)20 7496 3000 | ||
Jen Boorer / Patrick Weaver | |||
Walbrook PRΒ Limited | Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com | ||
Paul McManus / Alice WoodingsΒ | Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 | ||
Β
Β
Β
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
Β
EKF is an AIM-listed global diagnostics business focussed on:
Β
β | Point-of-CareΒ analysers in the key areas of Hematology and DiabetesΒ |
β | Life SciencesΒ services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications. |
Β
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.
Β
Β
Follow the stocks
